Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

BPH, LUTS & the ED Link

Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms, and Shared Erectile Mechanisms

Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.

The written rationale for this grade is still being prepared.

FDA
Not applicable (condition)

Reference only. Not medical advice.

This is something to take to a clinician. The Atlas can tell you what is known about bph, luts & the ed link in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.

Benign prostatic hyperplasia is near-universal with age: histological BPH is present in ~50% of men in their 50s and ~80-90% by their 80s, and roughly half of men with histologic BPH develop bothersome lower urinary tract symptoms (LUTS), weak stream, frequency, urgency, nocturia, incomplete emptying. Large epidemiologic studies (the Multinational Survey of the Aging Male, MSAM-7, 2003) found that LUTS severity independently predicts erectile dysfunction and ejaculatory dysfunction, even after adjusting for age and comorbidity. The relationship is not just 'both are old-man problems': they share mechanistic pathways.

The aging prostate and the aging erection travel together, and not by coincidence.

What people take it for

What it is taken for. Approval, where it exists, covers only some of these.

  • Recognizing LUTS as a sexual-health flag
  • Counseling before BPH treatment
  • Justifying combined LUTS/ED evaluation
LUTS evaluation
IPSS/AUA symptom index, uroflowmetry, post-void residual
Sexual-history screening
MSAM-7 data argue every BPH workup should ask about erections and ejaculation

How it works

Four overlapping mechanisms tie LUTS to ED. (1) Reduced nitric-oxide/cGMP signaling in both bladder and penile tissue, the same pathway PDE5 inhibitors target, which is why tadalafil is FDA-approved for both. (2) Increased RhoA/Rho-kinase activity, raising smooth-muscle tone in bladder, prostate, and penis. (3) Autonomic overactivity and pelvic atherosclerosis reducing perfusion to both organs. (4) Chronic ischemia and inflammation. Because the pathways overlap, treating one can affect the other for better (tadalafil) or worse (most BPH surgery and some drugs).

What people get wrong

  • Often saidA big prostate causes the symptoms

    ActuallySymptom bother correlates poorly with gland size; a small prostate can obstruct badly and a large one can be silent.

  • Often saidBPH is the same as prostate cancer

    ActuallyBPH is benign and arises in the transition zone; cancer is usually peripheral. BPH does not become cancer, though both can coexist.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

What we do not know

  • Does early treatment of LUTS slow ED progression, or are both simply markers of vascular aging?

At a glance

Histologic BPH by 50s
~50%
Histologic BPH by 80s
~80-90%
LUTS-ED link
Independent of age (MSAM-7, 2003)
Symptom score
IPSS / AUA-SI, 0-35
Bother
Tracks more with sexual dysfunction than gland size

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about BPH, LUTS & the ED Link. A short entry is not a safe entry.

  • Timeline. We have not built the dated record of research and regulatory events.
  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.
  • What can go wrong. We have not written the risk line for this one. Read the safety section below rather than treating its absence as reassurance.
  • Where we land. We have not taken a position on this yet.

Sources

The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.

The studies that matter

  • Rosen et al., MSAM-72003

    Across 12,815 men, LUTS severity was an independent risk factor for ED and ejaculatory dysfunction

  • McVary, LUTS/ED shared pathophysiology review2006

    Synthesized the NO/RhoK, autonomic, and ischemic links

  • Gacci et al., meta-analysis of PDE5i for LUTS2012

    PDE5 inhibitors improve both IPSS and erectile function scores